In Silico discovery of transcription factors as potential diagnostic biomarkers of ovarian cancer

被引:12
|
作者
Kaur, Mandeep [1 ]
MacPherson, Cameron R. [1 ]
Schmeier, Sebastian [1 ]
Narasimhan, Kothandaraman [2 ]
Choolani, Mahesh [3 ]
Bajic, Vladimir B. [1 ]
机构
[1] King Abdullah Univ Sci & Technol, Computat Biosci Res Ctr, Thuwal 239556900, Saudi Arabia
[2] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah 21589, Saudi Arabia
[3] Natl Univ Hlth Syst, Diagnost Biomarker Discovery Lab, Dept Obstet & Gynaecol, Yong Loo Lin Sch Med, Singapore 119074, Singapore
关键词
GENOME-WIDE ANALYSIS; GENE-EXPRESSION; ESTROGEN-RECEPTOR; RESPONSE ELEMENTS; MESSENGER-RNA; BREAST-CANCER; DATABASE; THERAPY; LETROZOLE; PROMOTER;
D O I
10.1186/1752-0509-5-144
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Our study focuses on identifying potential biomarkers for diagnosis and early detection of ovarian cancer (OC) through the study of transcription regulation of genes affected by estrogen hormone. Results: The results are based on a set of 323 experimentally validated OC-associated genes compiled from several databases, and their subset controlled by estrogen. For these two gene sets we computationally determined transcription factors (TFs) that putatively regulate transcription initiation. We ranked these TFs based on the number of genes they are likely to control. In this way, we selected 17 top-ranked TFs as potential key regulators and thus possible biomarkers for a set of 323 OC-associated genes. For 77 estrogen controlled genes from this set we identified three unique TFs as potential biomarkers. Conclusions: We introduced a new methodology to identify potential diagnostic biomarkers for OC. This report is the first bioinformatics study that explores multiple transcriptional regulators of OC-associated genes as potential diagnostic biomarkers in connection with estrogen responsiveness. We show that 64% of TF biomarkers identified in our study are validated based on real-time data from microarray expression studies. As an illustration, our method could identify CP2 that in combination with CA125 has been reported to be sensitive in diagnosing ovarian tumors.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer
    Gao, Ying-chun
    Wu, Jie
    TUMOR BIOLOGY, 2015, 36 (06) : 4843 - 4850
  • [42] Recent technical strategies to identify diagnostic biomarkers for ovarian cancer
    Ye, Bin
    Gagnon, Audrey
    Mok, Samuel C.
    EXPERT REVIEW OF PROTEOMICS, 2007, 4 (01) : 121 - 131
  • [43] The kallikrein proteins: New potential biomarkers for ovarian cancer
    Yousef, GM
    Katsaros, D
    Diamandis, EP
    LABORATORY INVESTIGATION, 2005, 85 : 209A - 209A
  • [44] Screening and prognostic value of potential biomarkers for ovarian cancer
    Li, Huiqin
    Li, Ming
    Tang, Chunhui
    Xu, Liang
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (12)
  • [45] The kallikrein proteins: New potential biomarkers for ovarian cancer
    Yousef, GM
    Katsaros, D
    Diamandis, EP
    MODERN PATHOLOGY, 2005, 18 : 209A - 209A
  • [46] Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer
    Gogoi, Radhika
    Srinivasan, Shankar
    Fishman, David A.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2006, 6 (04) : 627 - 637
  • [47] Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer
    Liu, Shuna
    Wu, Ming
    Wang, Fang
    JOURNAL OF CANCER, 2021, 12 (13): : 3976 - 3996
  • [48] Gene regulation by transcription factors and microRNAs in ovarian cancer
    Kuijjer, Marieke Lydia
    Glass, Kimberly
    Quackenbush, John
    CANCER RESEARCH, 2015, 75 (22)
  • [49] Targeting HOX and PBX transcription factors in ovarian cancer
    Richard Morgan
    Lynn Plowright
    Kevin J Harrington
    Agnieszka Michael
    Hardev S Pandha
    BMC Cancer, 10
  • [50] Targeting HOX and PBX transcription factors in ovarian cancer
    Morgan, Richard
    Plowright, Lynn
    Harrington, Kevin J.
    Michael, Agnieszka
    Pandha, Hardev S.
    BMC CANCER, 2010, 10